Kailera Therapeutics, Inc. has 5 Schedule 13D or 13G filings on record since 2026-04-23. 5 holders' latest filing reports 5% or more of common stock, $0.00001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BCPE Perseus Investor, LP | 20.27% | 26,255,581 | SCHEDULE 13D, 2026-04-23 | 2026-04-16 |
| BCLS Fund IV Investments, L.P. | 17.43% | 22,583,268 | SCHEDULE 13D, 2026-04-23 | 2026-04-16 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 8.9% | 11,511,853 | SCHEDULE 13G, 2026-08-05 | 2026-06-30 |
| RTW Investments, LP | 8.3% | 10,776,820 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| CPP Investment Board Private Holdings (4) Inc. | 5.6% | 7,304,688 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
Purpose of Transaction (Item 4)
BCPE Perseus Investor, LP
The information set forth in Item 3 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. Andrew Kaplan, a Partner of BCI, is a member of the Issuer's board of directors (the "Board"). The Reporting Person acquired the securities reported herein for investment purposes. In its capacity as a significant stockholder of the Issuer, the Reporting Person intends to take an active role in working with the Issuer's management and the Board on operational, financial and strategic initiatives. The Reporting Person reviews and intends to continue to review, on an ongoing and continuing basis, their investment in the Issuer. Depending upon the factors discussed below and subject to applicable law, the Reporting Person may from time to time acquire additional securities of the Issuer or sell or otherwise dispose of some or all of their securities of the Issuer. Any transactions that the Reporting Persons may pursue may be made at any time and from time to time without prior notice and will depend upon a variety of factors, including, without limitation, current and anticipated future trading prices of the securities of the Issuer, the financial condition, results of operations and prospects of the Issuer, general economic, financial market and industry conditions, other investment and business opportunities available to the Reporting Person, tax considerations and other factors.Item 4 of the SCHEDULE 13D filed 2026-04-23
BCLS Fund IV Investments, L.P.
The information set forth in Item 3 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. Adam Koppel, a Partner of BCLSI, is a member of the Issuer's board of directors (the "Board"). The Reporting Person acquired the securities reported herein for investment purposes. In its capacity as a significant stockholder of the Issuer, the Reporting Person intends to take an active role in working with the Issuer's management and the Board on operational, financial and strategic initiatives. The Reporting Person reviews and intends to continue to review, on an ongoing and continuing basis, their investment in the Issuer. Depending upon the factors discussed below and subject to applicable law, the Reporting Person may from time to time acquire additional securities of the Issuer or sell or otherwise dispose of some or all of their securities of the Issuer. Any transactions that the Reporting Persons may pursue may be made at any time and from time to time without prior notice and will depend upon a variety of factors, including, without limitation, current and anticipated future trading prices of the securities of the Issuer, the financial condition, results of operations and prospects of the Issuer, general economic, financial market and industry conditions, other investment and business opportunities avialable to the Reporting Person, tax considerations and other factors.Item 4 of the SCHEDULE 13D filed 2026-04-23
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-04-23 | BCPE Perseus Investor, LP | 20.27% | SCHEDULE 13D |
| 2026-04-23 | BCLS Fund IV Investments, L.P. | 17.43% | SCHEDULE 13D |
| 2026-08-05 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 8.9% | SCHEDULE 13G |
| 2026-08-14 | CPP Investment Board Private Holdings (4) Inc. | 5.6% | SCHEDULE 13G |
| 2026-08-14 | RTW Investments, LP | 8.3% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Kailera Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.